Revelation Biosciences Inc (REVB) - Total Assets
Based on the latest financial reports, Revelation Biosciences Inc (REVB) holds total assets worth $15.04 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Revelation Biosciences Inc to assess how comfortably operating cash covers total debt obligations.
Revelation Biosciences Inc - Total Assets Trend (2016–2025)
This chart illustrates how Revelation Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Revelation Biosciences Inc for net asset value and shareholders' equity analysis.
Revelation Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Revelation Biosciences Inc's total assets of $15.04 Million consist of 93.3% current assets and 6.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Revelation Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Revelation Biosciences Inc (REVB) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Revelation Biosciences Inc's current assets represent 93.3% of total assets in 2025, an increase from 0.0% in 2016.
- Cash Position: Cash and equivalents constituted 92.4% of total assets in 2025, up from 5.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Revelation Biosciences Inc Competitors by Total Assets
Key competitors of Revelation Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Revelation Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.02 | 3.61 | 2.43 |
| Quick Ratio | 10.02 | 3.61 | 2.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.79 Million | $2.84 Million | $4.74 Million |
Revelation Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Revelation Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 74.9% |
| Total Assets | $11.58 Million |
| Market Capitalization | $3.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Revelation Biosciences Inc's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Revelation Biosciences Inc's assets grew by 74.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Revelation Biosciences Inc (2016–2025)
The table below shows the annual total assets of Revelation Biosciences Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.58 Million | +74.91% |
| 2024-12-31 | $6.62 Million | -45.78% |
| 2023-12-31 | $12.21 Million | +121.91% |
| 2022-12-31 | $5.50 Million | +169.48% |
| 2021-12-31 | $2.04 Million | -55.80% |
| 2020-12-31 | $4.62 Million | +20280.22% |
| 2019-12-31 | $22.67K | -100.00% |
| 2018-12-31 | $2.46 Billion | +16.98% |
| 2017-12-31 | $2.10 Billion | +10.80% |
| 2016-12-31 | $1.89 Billion | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more